Wang, Y., Hou, L., Xu, Q., Xue, X., Pan, J., Qi, H., Fang, P., Mozley, P. D., Sartor, A. O., Yu, C. (2026). Phase I dose-escalation results of
                    <sup>177</sup>
                    Lu-NYM032 in patients with progressive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.5049